![Manfred Rüdiger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Manfred Rüdiger
Directeur/Membre du Conseil chez 4SC AG
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Kathleen Masch-Wiest | F | - | 2 ans | |
Pascal Schweizer | M | - |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Bernd Hentsch | M | 64 |
G2M Cancer Drugs AG
![]() G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | 23 ans |
Clemens M. Doppler | M | 64 | 19 ans | |
Ulrich Grau | M | 75 |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Irina Antonijevic | M | 59 | 12 ans | |
Gregory Mullen | M | 52 |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Hans-Jochem Kolb | M | - |
Minaris Regenerative Medicine GmbH
![]() Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Christoph Massner | M | - |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Florian Kirschenhofer | M | - |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Franz-Robert Klingan | M | - |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Lars Lindner | M | - |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Susanne Danhauser-Riedl | M | - | 9 ans | |
Helga Rübsamen-Schaeff | M | 75 | 9 ans | |
Helmut Jeggle | M | 53 | 16 ans | |
Jason Loveridge | M | 63 | 8 ans | |
Matthias Kromayer | M | 58 |
Minaris Regenerative Medicine GmbH
![]() Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Martin C. Münchbach | M | 54 |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | 3 ans |
Eduardo Bravo Fernández de Araoz | M | 58 |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | 3 ans |
Caroline Fichtner | M | - |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Olivier Litzka | M | 56 |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Joachim Rothe | M | - |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Per Anders Göte Samuelsson | M | 63 |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Jochen Knolle | M | 74 |
Thermosome GmbH
![]() Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany. | - |
Klaus Schollmeier | M | 67 |
Minaris Regenerative Medicine GmbH
![]() Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | - |
Jean-Patrick Hennebelle | M | - |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jörg Neermann | M | 57 |
LSP Services Deutschland GmbH
Technische Universität Braunschweig
| 15 ans |
Enno Spillner | M | 55 | 11 ans | |
Robert Soiffer | M | 66 | - | |
Stuart Chapman | M | 54 |
Kiadis Pharma BV
![]() Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | 3 ans |
Anna Niedl | M | - | 2 ans | |
Vincent Brichard | M | - | - | |
Berndt A. E. Modig | M | 65 | 5 ans | |
Petra Rück | M | - |
t2cure GmbH
![]() t2cure GmbH Medical/Nursing ServicesHealth Services t2cure GmbH develops progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiovascular diseases like myocardial infarction or peripheral vascular diseases. The company was founded by Andreas M. Zeiher and Stefanie Dimmeler n 2005 and is headquartered in Frankfurt, Germany. | - |
Ulrich Dauer | M | 59 | 16 ans | |
Arne Johannes Reif | M | 69 |
Eberhard Karls Universität Tübingen
| 12 ans |
Daniel Vitt | M | 55 | 19 ans | |
Matthias Victor | M | 54 |
Technische Universität Braunschweig
| 5 ans |
Frank Hermann | M | - | - | |
Susanne Lachenmann | M | 57 |
Eberhard Karls Universität Tübingen
| 4 ans |
Dietmar Oeter | M | 57 |
Eberhard Karls Universität Tübingen
| 3 ans |
Joerg von Petrikowsky | M | 66 | - | |
Rainer Kögel | M | 56 |
Eberhard Karls Universität Tübingen
| 3 ans |
Roland Weiger | M | 63 |
Eberhard Karls Universität Tübingen
| 4 ans |
Martin Wansleben | M | 65 |
Eberhard Karls Universität Tübingen
| 2 ans |
Karin Erhard | F | 63 |
Eberhard Karls Universität Tübingen
| 7 ans |
Matthias König | M | 56 |
Eberhard Karls Universität Tübingen
| 3 ans |
Jian Hui Gou | M | 62 |
Technische Universität Braunschweig
| 1 ans |
Martijn Kleijwegt | M | 69 | - | |
Lian Shan Zhang | M | 63 |
Eberhard Karls Universität Tübingen
| 6 ans |
Christoph Schubert | M | 63 |
Eberhard Karls Universität Tübingen
| 3 ans |
Iris Epple-Righi | F | 58 |
Eberhard Karls Universität Tübingen
| 4 ans |
Thomas Werner | M | 68 | 5 ans | |
Christoph Burkhard | M | 60 |
Eberhard Karls Universität Tübingen
| 4 ans |
Georgios Nikolaos Stamatelopoulos | M | 54 |
Technische Universität Braunschweig
| 3 ans |
Hella Kohlhof | M | 51 | - | |
Christian Kötz | M | 54 |
Technische Universität Braunschweig
| 4 ans |
Michael Roth | M | 57 |
Eberhard Karls Universität Tübingen
| 4 ans |
Heiko von der Leyen | M | - |
Cardion GmbH
![]() Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 3 ans |
Volkmar Tanneberger | M | 61 |
Technische Universität Braunschweig
| 4 ans |
Marion Hayes | F | - |
Technische Universität Braunschweig
| 4 ans |
Claudio Pediconi | M | - |
Ariceum Therapeutics GmbH
![]() Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | - |
Reiner Strecker | M | 63 |
Eberhard Karls Universität Tübingen
| 4 ans |
Hugo Hämmerle | M | 72 |
Eberhard Karls Universität Tübingen
| 3 ans |
Volker Hirsch | M | 56 |
Eberhard Karls Universität Tübingen
| 4 ans |
Francesco de Meo | M | 60 |
Eberhard Karls Universität Tübingen
| 3 ans |
Peter Stephen Keen | M | 66 |
Kiadis Pharma BV
![]() Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | - |
Eugen Stermetz | M | 52 |
Igeneon AG
| 4 ans |
Thomas Mathers | M | 56 |
Cardion GmbH
![]() Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 1 ans |
Cord Dohrmann | M | 60 |
Eberhard Karls Universität Tübingen
| 4 ans |
Alwin Epple | M | 61 |
Eberhard Karls Universität Tübingen
| 4 ans |
Andreas Hermann Renschler | M | 65 |
Eberhard Karls Universität Tübingen
| 3 ans |
Stefan Zoller | M | 66 |
Eberhard Karls Universität Tübingen
| 3 ans |
Brian D. Morgan | M | - | - | |
Jürgen Schuster | M | - |
Eberhard Karls Universität Tübingen
| 3 ans |
Herbert Seggewiss | M | - |
Eberhard Karls Universität Tübingen
| 2 ans |
Klaus Kühn | M | 72 | 2 ans | |
Philipp Daniel Merckle | M | 57 |
Eberhard Karls Universität Tübingen
| 4 ans |
Michael Meyer | M | 60 |
Technische Universität Braunschweig
| 3 ans |
Christoph Jurecka | M | 49 |
Technische Universität Braunschweig
| 3 ans |
Lutz Guderjahn | M | 58 |
Technische Universität Braunschweig
| 3 ans |
Bernhard Nick | M | 66 |
Eberhard Karls Universität Tübingen
| 3 ans |
Burkhard Lohr | M | 61 |
Technische Universität Braunschweig
| 3 ans |
Kai Richter | M | - |
Technische Universität Braunschweig
| 4 ans |
Robbert van Heekeren | M | 53 | 3 ans | |
Hubertine Underberg-Ruder | M | 62 |
Eberhard Karls Universität Tübingen
| 4 ans |
Thomas Nautsch | M | 67 |
Eberhard Karls Universität Tübingen
| 4 ans |
Manfred W. Schmolz | M | - |
Eberhard Karls Universität Tübingen
| 3 ans |
Robert Siegle | M | 57 |
Eberhard Karls Universität Tübingen
| 3 ans |
Günter Frankenne | M | - | 4 ans | |
Thomas H. Moll | M | 58 |
Cardion GmbH
![]() Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | 5 ans |
Eberhart Zrenner | M | - |
Eberhard Karls Universität Tübingen
| - |
Gregor Hagedorn | M | - |
Eberhard Karls Universität Tübingen
| 7 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Allemagne | 85 | 91,40% |
Pays-Bas | 7 | 7,53% |
Autriche | 1 | 1,08% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Manfred Rüdiger
- Réseau Personnel